Health ❯ Healthcare ❯ Clinical Trials

Cancer Treatment

Head and Neck Cancer Multiple Myeloma Immunotherapy Prostate Cancer CAR T-cell Therapy Breast Cancer Colorectal Cancer PARP Inhibitors Combination Therapy Chronic Lymphocytic Leukemia Survival Rates Pancreatic Cancer Targeted Therapies Solid Tumors Immunotherapy Strategies Sarcoma Endocrine Therapy Intensity-Modulated Radiation Therapy CAR-NK Cells Immunotherapy Research Drug Development Pan-Cancer Therapies Neuroendocrine Tumors Immunotherapy Trials Proton Beam Therapy Endometrial Cancer Immune Response Therapeutic Vaccines Innovative Therapies Drug Resistance ERAS-0015 Patient Enrollment Bruton Tyrosine Kinase Inhibitors Drug Efficacy HER2-positive Breast Cancer Advanced Colorectal Cancer Immunotherapy Drugs Personalized Medicine Androgen Therapy Recurrent Metastatic NPC Glioblastoma Trials Dormant Cells Biopharmaceuticals Acute Myeloid Leukemia Targeted Therapy Triple-Negative Breast Cancer CAR-NK Therapy CAR-T Therapy Immunotherapeutics CAR-T Cell Efficacy Small Lymphocytic Lymphoma (SLL) T-cell Therapy AML Treatment Strategies Skin Cancer Oncology FGFR2b-targeted Therapy Oropharyngeal Cancer EGFR-mutant NSCLC Ovarian Cancer Therapeutics Chronic Lymphocytic Leukemia (CLL) Radiation Therapy CAR T Therapy Gastrointestinal Cancers T Cell Therapies Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment AstraZeneca Tandem CAR T-cells Personalized Therapy Acupuncture CAR-T Cell Therapy BRAF Mutation

PROTEXI Vaccine Redirects COVID‑19 Immune Memory to Target Tumors

A peer‑reviewed preclinical study reports stronger tumor‑specific T‑cell responses and has prompted plans for a first‑in‑human sarcoma trial.

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Erasca Shares Plunge After Trial Death and Patent Challenge

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Androgen Signaling Drives Lethal Pediatric Ependymoma, Study Finds

Ligand-Based OSM CAR-T Shows Preclinical Efficacy Against Osteosarcoma

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

Acupuncture Improves Perceived Cognition With a Modest Memory Edge for Real Needling

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

TORPEdO Phase III Finds No One-Year Advantage for Proton Therapy Over IMRT in Oropharyngeal Cancer

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests